NUVA Stock - NuVasive, Inc.
Unlock GoAI Insights for NUVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $1.20B | $1.14B | $1.05B | $1.17B | $1.10B |
| Gross Profit | $865.43M | $816.71M | $728.95M | $855.71M | $790.55M |
| Gross Margin | 72.0% | 71.7% | 69.4% | 73.3% | 71.8% |
| Operating Income | $64.77M | $31.39M | $34.81M | $117.05M | $102.35M |
| Net Income | $40.41M | $-64,086,000 | $-37,153,000 | $65.23M | $12.48M |
| Net Margin | 3.4% | -5.6% | -3.5% | 5.6% | 1.1% |
| EPS | $0.78 | $-1.24 | $-0.72 | $1.26 | $0.24 |
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 10th 2023 | Wells Fargo | Downgrade | Equal Weight | $57.72 |
| February 10th 2023 | Citigroup | Downgrade | Neutral | $52← $63 |
| February 10th 2023 | Truist | Downgrade | Hold | $52.5← $51 |
| January 6th 2023 | Needham | Downgrade | Hold | - |
| October 18th 2022 | Barclays | Initiation | Overweight | $53 |
| October 12th 2022 | Jefferies | Initiation | Hold | $45 |
| April 13th 2022 | Truist | Resumed | Buy | $65← $60 |
Earnings History & Surprises
NUVAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Jul 31, 2024 | — | — | — | — |
Q2 2024 | May 8, 2024 | — | — | — | — |
Q1 2024 | Feb 20, 2024 | — | — | — | — |
Q4 2023 | Nov 8, 2023 | $0.54 | — | — | — |
Q3 2023 | Aug 2, 2023 | $0.56 | $0.56 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $0.41 | $0.47 | +14.6% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $0.51 | $0.43 | -15.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $0.53 | $0.54 | +1.9% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.55 | $0.47 | -14.5% | ✗ MISS |
Q2 2022 | May 4, 2022 | $0.38 | $0.54 | +42.1% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.47 | $0.40 | -14.9% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.54 | $0.32 | -40.7% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $0.43 | $0.60 | +39.5% | ✓ BEAT |
Q2 2021 | May 5, 2021 | $0.33 | $0.37 | +12.1% | ✓ BEAT |
Q1 2021 | Feb 25, 2021 | $0.55 | $0.59 | +7.3% | ✓ BEAT |
Q4 2020 | Oct 29, 2020 | $0.27 | $0.54 | +100.0% | ✓ BEAT |
Q3 2020 | Aug 4, 2020 | $0.49 | $0.40 | -18.4% | ✗ MISS |
Q2 2020 | May 6, 2020 | $0.35 | $0.48 | +37.1% | ✓ BEAT |
Q1 2020 | Feb 20, 2020 | $0.64 | $0.73 | +14.1% | ✓ BEAT |
Q4 2019 | Oct 30, 2019 | $0.54 | $0.59 | +9.3% | ✓ BEAT |
Latest News
Frequently Asked Questions about NUVA
What is NUVA's current stock price?
What is the analyst price target for NUVA?
What sector is NuVasive, Inc. in?
What is NUVA's market cap?
Does NUVA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NUVA for comparison